Equities Analysts Set Expectations for Arbutus Biopharma Corp’s Q3 2017 Earnings (ABUS)

Posted by Linda Flegge on Apr 22nd, 2017

Arbutus Biopharma Corp (NASDAQ:ABUS) – Equities researchers at Leerink Swann issued their Q3 2017 earnings estimates for Arbutus Biopharma Corp in a report issued on Wednesday, Zacks Investment Research reports. Leerink Swann analyst M. Schmidt forecasts that the biopharmaceutical company will earn ($0.42) per share for the quarter. Leerink Swann also issued estimates for Arbutus Biopharma Corp’s Q4 2017 earnings at ($0.44) EPS, FY2017 earnings at ($1.64) EPS and FY2018 earnings at ($1.30) EPS.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2017/04/22/equities-analysts-set-expectations-for-arbutus-biopharma-corps-q3-2017-earnings-abus.html.

Earnings History and Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS)

Several other equities research analysts have also commented on the stock. Chardan Capital raised shares of Arbutus Biopharma Corp from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $3.00 to $6.00 in a research note on Tuesday, April 4th. Zacks Investment Research lowered shares of Arbutus Biopharma Corp from a “hold” rating to a “sell” rating in a research note on Friday, January 27th. Wedbush dropped their target price on shares of Arbutus Biopharma Corp from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 1st. Finally, Bloom Burton upgraded shares of Arbutus Biopharma Corp from an “accumulate” rating to a “buy” rating in a research note on Monday, January 9th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.25.

Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) remained flat at $3.35 during mid-day trading on Friday. 187,149 shares of the company’s stock were exchanged. The stock has a 50 day moving average of $3.12 and a 200 day moving average of $2.88. The company’s market cap is $184.33 million. Arbutus Biopharma Corp has a 12 month low of $2.35 and a 12 month high of $5.48.

Hedge funds have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Arbutus Biopharma Corp by 1,058,889.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,294,945 shares of the biopharmaceutical company’s stock worth $12,972,000 after buying an additional 5,294,445 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Arbutus Biopharma Corp by 38.6% in the fourth quarter. Armistice Capital LLC now owns 1,940,000 shares of the biopharmaceutical company’s stock worth $4,753,000 after buying an additional 540,000 shares during the period. Bank of Montreal Can boosted its stake in shares of Arbutus Biopharma Corp by 6.3% in the third quarter. Bank of Montreal Can now owns 861,553 shares of the biopharmaceutical company’s stock worth $2,964,000 after buying an additional 50,768 shares during the period. Baker BROS. Advisors LP purchased a new stake in shares of Arbutus Biopharma Corp during the third quarter worth about $621,000. Finally, Oxford Asset Management purchased a new stake in shares of Arbutus Biopharma Corp during the fourth quarter worth about $392,000. 61.24% of the stock is owned by institutional investors and hedge funds.

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).